Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Colorectal Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 105 articles:
HTML format



Single Articles


    April 2021
  1. KANIKARLA MARIE P, Haymaker C, Parra ER, Kim YU, et al
    Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.
    Clin Cancer Res. 2021 Apr 2. pii: 1078-0432.CCR-21-0163.
    PubMed     Abstract available


    March 2021
  2. ARAI H, Elliott A, Xiu J, Wang J, et al
    The landscape of alterations in DNA damage response pathways in colorectal cancer.
    Clin Cancer Res. 2021 Mar 25. pii: 1078-0432.CCR-20-3635.
    PubMed     Abstract available


    February 2021
  3. KAGAWA Y, Fernandez EE, Garcia-Foncillas J, Bando H, et al
    Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study.
    Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-3677.
    PubMed     Abstract available


  4. MONJAZEB AM, Giobbie-Hurder A, Lako A, Thrash EM, et al
    A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-4632.
    PubMed     Abstract available


  5. MANCA P, Corallo S, Busico A, Lonardi S, et al
    The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer.
    Clin Cancer Res. 2021 Feb 5. pii: 1078-0432.CCR-20-4699.
    PubMed     Abstract available


    January 2021
  6. MOOI J, Chionh F, Savas P, Da Gama Duarte J, et al
    Dual anti-angiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study.
    Clin Cancer Res. 2021 Jan 29. pii: 1078-0432.CCR-20-2714.
    PubMed     Abstract available


  7. SEGAL NH, Cercek A, Ku GY, Wu AJ, et al
    Phase II Single Arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair Proficient Metastatic Colorectal Cancer.
    Clin Cancer Res. 2021 Jan 27. pii: 1078-0432.CCR-20-2474.
    PubMed     Abstract available


  8. COUSIN S, Cantarel C, Guegan JP, Gomez-Roca C, et al
    Regorafenib-Avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE) : a single arm, open-label, phase II trial.
    Clin Cancer Res. 2021 Jan 25. pii: 1078-0432.CCR-20-3416.
    PubMed     Abstract available


  9. MEHRVARZ SARSHEKEH A, Alshenaifi J, Roszik J, Manyam G, et al
    ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer.
    Clin Cancer Res. 2021 Jan 7. pii: 1078-0432.CCR-20-2404.
    PubMed     Abstract available


    December 2020
  10. ABRAHAM JP, Magee D, Cremolini C, Antoniotti C, et al
    Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer.
    Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-3286.
    PubMed     Abstract available


    November 2020
  11. BARRIUSO J, Nagaraju RT, Belgamwar S, Chakrabarty B, et al
    Early adaptation of colorectal cancer cells to the peritoneal cavity is associated with activation of 'stemness' programs and local inflammation.
    Clin Cancer Res. 2020 Nov 30. pii: 1078-0432.CCR-20-3320.
    PubMed     Abstract available


  12. JACOBS SA, Lee JJ, George TJ, Wade JL, et al
    Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
    Clin Cancer Res. 2020 Nov 17. pii: 1078-0432.CCR-20-1831.
    PubMed     Abstract available


  13. JIFFRY J, Thavornwatanayong T, Rao D, Fogel EJ, et al
    Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancer.
    Clin Cancer Res. 2020 Nov 9. pii: 1078-0432.CCR-20-2385.
    PubMed     Abstract available


    October 2020
  14. LOREE JM, Dowers A, Tu D, Jonker D, et al
    Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial.
    Clin Cancer Res. 2020 Oct 21. pii: 1078-0432.CCR-20-2710.
    PubMed     Abstract available


  15. XIE H, Mahoney DW, Foote PH, Burger KN, et al
    Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.
    Clin Cancer Res. 2020 Oct 7. pii: 1078-0432.CCR-20-2589.
    PubMed     Abstract available


  16. MALLA SB, Fisher D, Domingo E, Blake A, et al
    In-depth clinical and biological exploration of DNA Damage Immune Response (DDIR) as a biomarker for oxaliplatin use in colorectal cancer.
    Clin Cancer Res. 2020 Oct 7. pii: 1078-0432.CCR-20-3237.
    PubMed     Abstract available


    September 2020
  17. MAITLAND ML, Wilkerson J, Karovic S, Zhao B, et al
    Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-1493.
    PubMed     Abstract available


  18. NUSRAT M
    Response to anti-PD-1 in microsatellite stable colorectal cancer: a STAT need.
    Clin Cancer Res. 2020 Sep 21. pii: 1078-0432.CCR-20-2901.
    PubMed     Abstract available


  19. INNOCENTI F, Sibley AB, Patil SA, Etheridge AS, et al
    Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance).
    Clin Cancer Res. 2020 Sep 21. pii: 1078-0432.CCR-20-2021.
    PubMed     Abstract available


  20. STAHLER A, Stintzing S, Modest DP, Ricard I, et al
    Amphiregulin expression is a predictive biomarker for EGFR inhibition in metastatic colorectal cancer: combined analysis of three randomized trials.
    Clin Cancer Res. 2020 Sep 17. pii: 1078-0432.CCR-20-2748.
    PubMed     Abstract available


  21. DE GOOYER JM, Elekonawo FMK, Bos DL, van der Post RS, et al
    Multimodal CEA-targeted image-guided colorectal cancer surgery using 111In-labeled SGM-101.
    Clin Cancer Res. 2020 Sep 8. pii: 1078-0432.CCR-20-2255.
    PubMed     Abstract available


    July 2020
  22. KAWAZOE A, Kuboki Y, Shinozaki E, Hara H, et al
    Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial).
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1803.
    PubMed     Abstract available


  23. RANDON G, Pagani F, Pietrantonio F
    MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Response.
    Clin Cancer Res. 2020;26:3495.
    PubMed    


  24. OTTAIANO A, Caraglia M
    MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Letter.
    Clin Cancer Res. 2020;26:3493-3494.
    PubMed    


    June 2020
  25. CHU JE, Johnson B, Kugathasan L, Morris VK, et al
    Population-based screening for BRAF (V600E) in metastatic colorectal cancer reveals increased prevalence and poor prognosis.
    Clin Cancer Res. 2020 Jun 22. pii: 1078-0432.CCR-20-1024.
    PubMed     Abstract available


    May 2020
  26. VAYRYNEN JP, Lau MC, Haruki K, Vayrynen SA, et al
    Prognostic significance of immune cell populations identified by machine learning in colorectal cancer using routine hematoxylin & eosin stained sections.
    Clin Cancer Res. 2020 May 21. pii: 1078-0432.CCR-20-0071.
    PubMed     Abstract available


  27. MCCUAIG S, Barras D, Mann E, Friedrich M, et al
    The interleukin 22 pathway interacts with mutant KRAS to promote poor prognosis in colon cancer.
    Clin Cancer Res. 2020 May 19. pii: 1078-0432.CCR-19-1086.
    PubMed     Abstract available


  28. MATHUR D, Root AR, Bugaj-Gaweda B, Bisulco S, et al
    A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
    Clin Cancer Res. 2020;26:2188-2202.
    PubMed     Abstract available


    April 2020
  29. LAKINS MA, Koers A, Giambalvo R, Munoz-Olaya J, et al
    FS222, a CD137/PD-L1 tetravalent bispecific antibody exhibits low toxicity and anti-tumor activity in colorectal cancer models.
    Clin Cancer Res. 2020 Apr 28. pii: 1078-0432.CCR-19-2958.
    PubMed     Abstract available


  30. KIM RD, Azad NS, Morse MA, Poplin E, et al
    Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer.
    Clin Cancer Res. 2020 Apr 17. pii: 1078-0432.CCR-20-0426.
    PubMed     Abstract available


  31. BRUUN J, Kryeziu K, Eide PW, Moosavi SH, et al
    Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity.
    Clin Cancer Res. 2020 Apr 16. pii: 1078-0432.CCR-19-3637.
    PubMed     Abstract available


  32. MORRIS VK, Bekaii-Saab T
    Improvements in Clinical Outcomes for BRAFV600E-mutant Metastatic Colorectal Cancer.
    Clin Cancer Res. 2020 Apr 6. pii: 1078-0432.CCR-19-3809.
    PubMed     Abstract available


    March 2020
  33. MAX MA X, Bendell JC, Hurwitz HI, Ju C, et al
    Disease Monitoring Using Post-Induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-19-1209.
    PubMed     Abstract available


  34. RICKELT S, Condon C, Mana M, Whittaker C, et al
    Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions.
    Clin Cancer Res. 2020;26:1277-1287.
    PubMed     Abstract available


  35. ARENA S, Corti G, Durinikova E, Montone M, et al
    A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
    Clin Cancer Res. 2020;26:1372-1384.
    PubMed     Abstract available


    February 2020
  36. YOO SY, Park HE, Kim JH, Wen X, et al
    Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor-Immune Microenvironment in Colorectal Cancers.
    Clin Cancer Res. 2020;26:870-881.
    PubMed     Abstract available


  37. CAPDEVILA J, Arques O, Hernandez Mora JR, Matito J, et al
    Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas.
    Clin Cancer Res. 2020;26:902-909.
    PubMed     Abstract available


  38. MIDDLETON G, Yang Y, Campbell CD, Andre T, et al
    BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.
    Clin Cancer Res. 2020 Feb 11. pii: 1078-0432.CCR-19-3579.
    PubMed     Abstract available


  39. VAN CUTSEM E, Paccard C, Chiron M, Tabernero J, et al
    Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial.
    Clin Cancer Res. 2020;26:717-725.
    PubMed     Abstract available


  40. HICKS KC, Knudson KM, Lee KL, Hamilton DH, et al
    Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Clin Cancer Res. 2020;26:704-716.
    PubMed     Abstract available


    January 2020
  41. KHAKOO S, Carter PD, Brown G, Valeri N, et al
    MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
    Clin Cancer Res. 2020;26:183-192.
    PubMed     Abstract available


    November 2019
  42. PIETRANTONIO F, Lobefaro R, Antista M, Lonardi S, et al
    Capecitabine and temozolomide versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer.
    Clin Cancer Res. 2019 Nov 18. pii: 1078-0432.CCR-19-3024.
    PubMed     Abstract available


  43. DATTA J, Smith JJ, Chatila WK, McAuliffe JC, et al
    Co-Altered Ras/B-raf and TP53 is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Metastatic Colorectal Cancer Patients.
    Clin Cancer Res. 2019 Nov 12. pii: 1078-0432.CCR-19-2390.
    PubMed     Abstract available


    October 2019
  44. WANG S, Huang J, Li C, Zhao L, et al
    MAP9 loss triggers chromosomal instability, initiates colorectal tumorigenesis and is associated with poor survival of colorectal cancer patients.
    Clin Cancer Res. 2019 Oct 29. pii: 1078-0432.CCR-19-1611.
    PubMed     Abstract available


    September 2019
  45. YUAN C, Sato K, Hollis BW, Zhang S, et al
    Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-0877.
    PubMed     Abstract available


  46. YAEGER R, Kotani D, Mondaca S, Parikh AR, et al
    Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-2004.
    PubMed     Abstract available


  47. LLOSA NJ, Luber B, Tam AJ, Smith KN, et al
    Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.
    Clin Cancer Res. 2019;25:5250-5259.
    PubMed     Abstract available


    August 2019
  48. ANGELL HK, Bruni D, Barrett JC, Herbst R, et al
    The Immunoscore: Colon Cancer and Beyond.
    Clin Cancer Res. 2019 Aug 14. pii: 1078-0432.CCR-18-1851.
    PubMed     Abstract available


  49. LAZZARI L, Corti G, Picco G, Isella C, et al
    Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-18-3440.
    PubMed     Abstract available


    July 2019
  50. LEE DW, Han SW, Bae JM, Jang H, et al
    Tumor Mutation Burden and Prognosis in Colorectal Cancer Patients Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-1105.
    PubMed     Abstract available


  51. WILLIS JA, Overman MJ, Vilar E
    Mismatch repair-proficient colorectal cancer: finding the right TiME to respond.
    Clin Cancer Res. 2019 Jul 1. pii: 1078-0432.CCR-19-1447.
    PubMed     Abstract available


    June 2019
  52. LIEU CH, Golemis EA, Serebriiskii IG, Newberg JY, et al
    Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.
    Clin Cancer Res. 2019 Jun 26. pii: 1078-0432.CCR-19-0899.
    PubMed     Abstract available


  53. FREIRE VALLS A, Knipper K, Giannakouri E, Sarachaga V, et al
    VEGFR1(+) metastasis-associated macrophages contribute to metastatic angiogenesis and influence colorectal cancer patient outcome.
    Clin Cancer Res. 2019 Jun 25. pii: 1078-0432.CCR-18-2123.
    PubMed     Abstract available


    April 2019
  54. PISKOL R, Huw LY, Sergin I, Klijn C, et al
    A Clinical Applicable Gene Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
    Clin Cancer Res. 2019 Apr 19. pii: 1078-0432.CCR-18-3032.
    PubMed     Abstract available


  55. FENG Q, Chang W, Mao Y, He G, et al
    Tumor-associated macrophages as prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer.
    Clin Cancer Res. 2019 Apr 15. pii: 1078-0432.CCR-18-2076.
    PubMed     Abstract available


  56. WANG XC, Yue X, Zhang R, Liu TY, et al
    Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating non-homologous end joining repair.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3735.
    PubMed     Abstract available


  57. DIAZ-MAROTO NG, Sanz-Pamplona R, Berdiel-Acer M, Cimas FJ, et al
    Non-canonical TGFb pathway relieves the blockade of IL-1b/TGFb-mediated crosstalk between tumour and stroma: TGFBR1TAK1 inhibition in colorectal cancer.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3957.
    PubMed     Abstract available


  58. SCHIRRIPA M, Biason P, Lonardi S, Pella N, et al
    Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization.
    Clin Cancer Res. 2019 Apr 9. pii: 1078-0432.CCR-19-0311.
    PubMed     Abstract available


  59. ANANDAPPA G, Lampis A, Cunningham D, Khan KH, et al
    MicroRNA 31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-18-3769.
    PubMed     Abstract available


  60. MORRIS VK
    Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral.
    Clin Cancer Res. 2019;25:2030-2032.
    PubMed     Abstract available


    February 2019
  61. SIRAVEGNA G, Sartore-Bianchi A, Nagy RJ, Raghav K, et al
    Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-3389.
    PubMed     Abstract available


    January 2019
  62. OGAWA R, Yamamoto T, Hirai H, Hanada K, et al
    Loss of SMAD4 promotes colorectal cancer progression by recruiting tumor-associated neutrophils via CXCL1/8-CXCR2 axis.
    Clin Cancer Res. 2019 Jan 31. pii: 1078-0432.CCR-18-3684.
    PubMed     Abstract available


  63. TOKUNAGA R, Xiu J, Johnston C, Goldberg RM, et al
    Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer.
    Clin Cancer Res. 2019 Jan 28. pii: 1078-0432.CCR-18-3388.
    PubMed     Abstract available


    December 2018
  64. WASSERMAN I, Lee LH, Ogino S, Marco MR, et al
    SMAD4 loss in colorectal cancer patients correlates with recurrence, loss of immune infiltrate, and chemoresistance.
    Clin Cancer Res. 2018 Dec 26. pii: 1078-0432.CCR-18-1726.
    PubMed     Abstract available


  65. YANG W, Ma Y, Smith-Warner SA, Song M, et al
    Calcium intake and survival after colorectal cancer diagnosis.
    Clin Cancer Res. 2018 Dec 13. pii: 1078-0432.CCR-18-2965.
    PubMed     Abstract available


    November 2018
  66. PEETERS M, Price T, Boedigheimer M, Kim TW, et al
    Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Treated With Panitumumab in the ASPECCT Study.
    Clin Cancer Res. 2018 Nov 28. pii: 1078-0432.CCR-18-2072.
    PubMed     Abstract available


  67. PARK SY, Kim JY, Choi JH, Kim JH, et al
    Inhibition of LEF1-mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
    Clin Cancer Res. 2018 Nov 16. pii: 1078-0432.CCR-18-1232.
    PubMed     Abstract available


    October 2018
  68. LEE LY, Woolley CE, Starkey T, Biswas S, et al
    SERUM- AND GLUCOCORTICOID-INDUCED KINASE SGK1 DIRECTLY PROMOTES THE DIFFERENTIATION OF COLORECTAL CANCER CELLS AND RESTRAINS METASTASIS.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1033.
    PubMed     Abstract available


    September 2018
  69. PARIKH AR, Lee FC, Yau L, Koh H, et al
    MAVERICC, a randomized, biomarker-stratified, phase 2 study of mFOLFOX6-bevacizumab vs FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1221.
    PubMed     Abstract available


    August 2018
  70. LAURENT-PUIG P, Grisoni ML, Heinemann V, Liebaert F, et al
    Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1324.
    PubMed     Abstract available


  71. LEE V, Wang JS, Zahurak ML, Gootjes EC, et al
    A phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan.
    Clin Cancer Res. 2018 Aug 10. pii: 1078-0432.CCR-18-0421.
    PubMed     Abstract available


    June 2018
  72. PAAUWE M, Schoonderwoerd MJ, Helderman RFCPA, Harryvan TJ, et al
    Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-18-0329.
    PubMed     Abstract available


  73. GALLOIS C, Taieb J, Le Corre D, Le Malicot K, et al
    Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy.
    Clin Cancer Res. 2018 Jun 19. pii: 1078-0432.CCR-18-0866.
    PubMed     Abstract available


  74. BIAN Z, Zhang J, Li M, Feng Y, et al
    LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling.
    Clin Cancer Res. 2018 Jun 18. pii: 1078-0432.CCR-17-2967.
    PubMed     Abstract available


  75. KIM TW, Peeters M, Thomas AL, Gibbs P, et al
    Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer.
    Clin Cancer Res. 2018 Jun 13. pii: 1078-0432.CCR-17-3377.
    PubMed     Abstract available


    May 2018
  76. NODA M, Okayama H, Tachibana K, Sakamoto W, et al
    Glycosyltransferase gene expression identifies a poor prognostic colorectal cancer subtype associated with mismatch repair deficiency and incomplete glycan synthesis.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-17-3533.
    PubMed     Abstract available


  77. TOWNSEND A, Tebbutt NC, Karapetis CS, Cooper P, et al
    PHASE IB/II STUDY OF SECOND LINE THERAPY WITH PANITUMUMAB, IRINOTECAN AND EVEROLIMUS (PIE) IN KRAS WILD TYPE METASTATIC COLORECTAL CANCER.
    Clin Cancer Res. 2018 May 8. pii: 1078-0432.CCR-17-3590.
    PubMed     Abstract available


    April 2018
  78. RODRIGUEZ J, Vicent S, Chopitea A, Ponz-Sarvise M, et al
    Adjuvant therapy for colon cancer: genes, genes... and the patient in the center.
    Clin Cancer Res. 2018 Apr 20. pii: 1078-0432.CCR-18-0818.
    PubMed     Abstract available


    March 2018
  79. TOLEDO RA, Garralda E, Mitsi M, Pons T, et al
    Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of anti-angiogenic therapies.
    Clin Cancer Res. 2018 Mar 27. pii: 1078-0432.CCR-18-0103.
    PubMed     Abstract available


  80. MURCIA O, Jover R, Egoavil CM, Juarez M, et al
    TFAP2E Methylation and Expression Status Does Not Predict Response to 5FU-based Chemotherapy in Colorectal Cancer.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-2940.
    PubMed     Abstract available


  81. KANDIMALLA R, Gao F, Matsuyama T, Ishikawa T, et al
    Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-3236.
    PubMed     Abstract available


  82. HILL AG, Findlay M, Burge M, Jackson C, et al
    Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.
    Clin Cancer Res. 2018 Mar 5. pii: 1078-0432.CCR-17-0646.
    PubMed     Abstract available


    February 2018
  83. MESANGE P, Bouygues A, Ferrand N, Sabbah M, et al
    Combinations of Bevacizumab and Erlotinib show activity in colorectal cancer independent of RAS status.
    Clin Cancer Res. 2018 Feb 28. pii: 1078-0432.CCR-17-3187.
    PubMed     Abstract available


  84. HAYNES J, McKee TD, Haller AC, Wang Y, et al
    Administration of Hypoxia-Activated Prodrug Evofosfamide after Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Colorectal Cancer.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-1715.
    PubMed     Abstract available


  85. LI X, Wang Q, Gao X, Yu T, et al
    REGgamma controls Hippo signaling and reciprocal NF-kappaB-YAP regulation to promote colon cancer.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2986.
    PubMed     Abstract available


  86. LAMPRECHT S, Kaller M, Schmidt EM, Blaj C, et al
    PBX3 is part of an EMT regulatory network and indicates poor outcome in colorectal cancer.
    Clin Cancer Res. 2018 Feb 1. pii: 1078-0432.CCR-17-2572.
    PubMed     Abstract available


    January 2018

  87. Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
    Clin Cancer Res. 2018;24:499.
    PubMed    


  88. MARSHALL JF
    Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
    Clin Cancer Res. 2018;24:253-255.
    PubMed     Abstract available


    December 2017
  89. LIANG Q, Ma D, Zhu X, Wang Z, et al
    RING-finger protein 6 amplification activates JAK/STAT3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer.
    Clin Cancer Res. 2017 Dec 29. pii: 1078-0432.CCR-17-2133.
    PubMed     Abstract available


  90. DIENSTMANN R
    Tumor side as model of integrative molecular classification of colorectal cancer.
    Clin Cancer Res. 2017 Dec 21. pii: 1078-0432.CCR-17-3477.
    PubMed     Abstract available


  91. SVEEN A, Bruun J, Eide PW, Eilertsen IA, et al
    Colorectal cancer Consensus Molecular Subtypes translated to preclinical models uncover potentially targetable cancer-cell dependencies.
    Clin Cancer Res. 2017 Dec 14. pii: 1078-0432.CCR-17-1234.
    PubMed     Abstract available


  92. BERGER MD, Stintzing S, Heinemann V, Cao S, et al
    A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1663.
    PubMed     Abstract available


  93. ULINTZ PJ, Greenson JK, Wu R, Fearon ER, et al
    Lymph Node Metastases in Colon Cancer are Polyclonal.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-1425.
    PubMed     Abstract available


  94. CARNERO A, Lucena-Cacace A, Otero-Albiol D, Jimenez-Garcia MP, et al
    NAMPT is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and resistance to therapy through Sirt1 and PARP.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-2575.
    PubMed     Abstract available


    November 2017
  95. LOREE JM, Pereira AA, Lam M, Willauer AN, et al
    Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2484.
    PubMed     Abstract available


    October 2017
  96. GROTHEY A, Strosberg JR, Renfro LA, Hurwitz HI, et al
    A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Ontuxizumab (MORAb-004) in Patients with Chemorefractory Metastatic Colorectal Cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.1558.2017.
    PubMed     Abstract available


  97. LAL N, White BS, Goussous G, Pickles OJ, et al
    KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1090.2017.
    PubMed     Abstract available


  98. BOCCACCIO C, Luraghi P, Bigatto V, Cipriano E, et al
    A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.2151.2017.
    PubMed     Abstract available


    September 2017
  99. KANG DW, Lee BH, Suh YA, Choi YS, et al
    Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by Wnt/beta-catenin and PI3K/Akt Signaling.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0749.2017.
    PubMed     Abstract available


  100. JOUNG JG, Oh BY, Hong HK, AlKhalidi H, et al
    Tumor heterogeneity predicts metastatic potential in colorectal cancer.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0306.2017.
    PubMed     Abstract available


  101. YIN Y, Yao S, Hu Y, Feng Y, et al
    The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-derived IL-6.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1283.2017.
    PubMed     Abstract available


  102. BARTOLOME RA, Aizpurua C, Jaen M, Torres S, et al
    Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1444.2017.
    PubMed     Abstract available


  103. JIAO HL, Ye YP, Yang RW, Sun HY, et al
    Down-regulation of SAFB sustains the NF-kappaB pathway by targeting TAK1 during the progression of colorectal cancer.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0747.2017.
    PubMed     Abstract available


    March 2017
  104. PAKISH JB, Zhang Q, Chen Z, Liang H, et al
    Immune microenvironment in microsatellite instable endometrial cancers: Hereditary or sporadic origin matters.
    Clin Cancer Res. 2017 Mar 6. pii: clincanres.2655.2016.
    PubMed     Abstract available


  105. PICHLER M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, et al
    Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.
    Clin Cancer Res. 2017;23:1323-1333.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: